Prospective, Multicenter, Non-randomized, Single Arm Clinical Trial to Evaluate the Safety and Efficacy of e-PTFE Grafts Inner Surface-treated With Paclitaxel as an Access for Hemodialysis in Patients With End-stage Renal Disease.

Last updated: February 24, 2020
Sponsor: Samsung Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT04285073
SMC 2018-03-017
  • Ages 20-80
  • All Genders

Study Summary

This prospective, multicenter, non-randomized, single-arm Clinical trial aims to evaluate the safety and effectiveness of the use of paclitaxel-coated arteriovenous graft (AVG) on the inner wall of ePTFE graft, which is designed to reduce neointimal hyperplasia that causes stenosis and thrombosis after implantation of AVG.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult male or female between the ages of 20 and 80

  • Patients currently undergoing or scheduled for hemodialysis due to end-stage kidneydisease.

  • Patients who decided to receive AVG procedure in forearm due to inability to performautologous arteriovenous fistula (AVF)

  • Patients with a high risk of stenosis (neointimal hyperplasia) or thrombosis whenartificial blood vessels were implanted

Exclusion

Exclusion Criteria:

  • Pregnant or lactating women

  • Patients who are currently diagnosed with malignant tumors and are receivingchemotherapy or radiotherapy

  • Patients with life expectancy less than 12 months

  • Patients expected to receive a kidney transplant during the trial

  • Patients with current or suspected infection

  • Acute psychiatric problems require treatment

  • Patients who have inserted a catheter into an artery or vein in their upper limb forAVG procedure within the last 30 days

  • Patients with coagulation disorder, platelet count <50,000 / Ul

  • Patients with a neutrophil count of less than 1,500 cells / mm3

  • Patients judged to be unable to insert grafts by the operator

Study Design

Total Participants: 20
Study Start date:
November 13, 2018
Estimated Completion Date:
December 31, 2023

Study Description

  1. Evaluation of safety Primary outcome: all adverse events occurring in the subject

  2. Evaluation of effectiveness Primary outcome: AV graft primary patency Secondary outcome: AV graft secondary patency

Connect with a study center

  • Samsung Medical Center

    Seoul, 135-710
    Korea, Republic of

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.